| 摘要: |
| ［摘要］ 子宫内膜癌作为女性生殖系统恶性肿瘤之一，其晚期及复发患者的生存率显著下降，传统的系统治疗包括化疗和内分泌治疗。约90%的子宫内膜癌呈激素受体阳性。对于进展缓慢的激素受体阳性子宫内膜癌，内分泌治疗是首选的系统治疗方案。中国医师协会妇产科医师分会妇科肿瘤学组组织编写了《复发性子宫内膜癌内分泌治疗中国专家共识（2024年版）》，从复发性子宫内膜癌的临床表现、诊断以及内分泌治疗等方面进行了推荐，旨在规范复发性子宫内膜癌的内分泌治疗实践。 |
| 关键词: 复发性子宫内膜癌 内分泌治疗 激素受体 联合治疗 专家共识 解读 |
| DOI：10.3969/j.issn.1674-3806.2025.05.05 |
| 分类号:R 737.33 |
| 基金项目:“科大新医学”联合资金资助项目（编号：YD9110002049）；安徽省自然科学基金项目（编号：2408085MH207）；新型生命医学成像与智能处理安徽省重点实验室开放课题（编号：2024KY414）；安徽省临床重点专科基金项目（编号：2022sjlczdzk） |
|
| Interpretation of Chinese Expert Consensus on Endocrine Therapy for Recurrent Endometrial Cancer(2024 Edition) |
|
CHEN Yao1, WANG Zengying2, WANG Yumeng2, XIA Bairong1,2
|
|
1.Department of Gynecologic Oncology Surgery, Western Branch,the First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China; 2.Graduate School, Bengbu Medical University, Bengbu 233000, China
|
| Abstract: |
| ［Abstract］ Endometrial cancer is one of the malignant tumors of the female reproductive system, and the survival rate of the patients with advanced and recurrent endometrial cancer was significantly decreased. Traditional systemic therapies include chemotherapy and endocrine therapy. Approximately 90% of endometrial cancers are hormone receptor-positive. For slow-progressing, hormone receptor-positive endometrial cancers, endocrine therapy is the preferred first-line systemic therapy option. The Gynecologic Oncology Group of Chinese Medical Doctor Association Obstetricians and Gynecologists Branch organized the compilation of Chinese Expert Consensus on Endocrine Therapy for Recurrent Endometrial Cancer(2024 Edition), providing evidence-based recommendations covering the clinical manifestations, diagnosis, and endocrine therapy of recurrent endometrial cancer. This consensus aims to standardize endocrine therapy practice for recurrent endometrial cancer in clinical settings. |
| Key words: Recurrent endometrial cancer Endocrine therapy Hormone receptor Combination therapy Expert consensus Interpretation |
